Replies to post #103939 on Biotech Values

[mouton29]

Yes, well the same article makes this statenment:

Idenix, another hepatitis drug developer, was the third-best-performing stock among biotechs in August. Its stock popped after it released abstracts for a medical meeting to be held by the American Association for the Study of Liver Diseases in October, and investors liked what they saw

I suppose this is true, but for something published today, you might think a little qualification would be in order.

[ilpapa]

Thanks, I was worried I'd slipped another gear somewhere. Must be delay between submission and publication.